These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1723534)

  • 1. Tumor-associated trypsin inhibitor in pancreatic diseases.
    Aroasio E; Piantino P
    Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    J Cancer Res Clin Oncol; 1994; 120(8):494-7. PubMed ID: 8207049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
    Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
    Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases.
    Piantino P; Arosaio E
    Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.
    Masson P; Pålsson B; Andren-Sandberg A
    Int J Pancreatol; 1991 May; 8(4):333-44. PubMed ID: 1791319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of TATI and other markers in solid tumors.
    Taccone W; Mazzon W; Belli M
    Scand J Clin Lab Invest Suppl; 1991; 207():25-32. PubMed ID: 1780686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.
    Plebani M; Basso D; Fabris C; Meggiato T; Del Favero G; Panozzo MP; Fogar P; Faggian D; Angonese C; Burlina A
    Klin Wochenschr; 1989 Oct; 67(20):1029-32. PubMed ID: 2586008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
    Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
    Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases.
    Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman UH; Isoniemi H
    Tumour Biol; 2018 Jan; 40(1):1010428317752944. PubMed ID: 29378497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA.
    Cerwenka H; Aigner R; Quehenberger F; Werkgartner G; Bacher H; Hauser H; Mischinger HJ
    Hepatogastroenterology; 1997; 44(16):1117-21. PubMed ID: 9261609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
    Catarino M; Conde R
    Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening.
    Järvisalo J; Hakama M; Knekt P; Stenman UH; Leino A; Teppo L; Maatela J; Aromaa A
    Cancer; 1993 Mar; 71(6):1982-8. PubMed ID: 8443749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
    Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
    Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
    Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
    Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L; Zhang Y; Chen M; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
    Haglund C; Lundin J; Kuusela P; Roberts PJ
    Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
    de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
    Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA 494--a new tumor marker for the diagnosis of pancreatic cancer.
    Friess H; Büchler M; Auerbach B; Weber A; Malfertheiner P; Hammer K; Madry N; Greiner S; Bosslet K; Beger HG
    Int J Cancer; 1993 Mar; 53(5):759-63. PubMed ID: 8449599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.